SG165379A1 - Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects - Google Patents

Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects

Info

Publication number
SG165379A1
SG165379A1 SG201006668-6A SG2010066686A SG165379A1 SG 165379 A1 SG165379 A1 SG 165379A1 SG 2010066686 A SG2010066686 A SG 2010066686A SG 165379 A1 SG165379 A1 SG 165379A1
Authority
SG
Singapore
Prior art keywords
tetrazolylalkoxy
effects
superoxide
supressant
combination drug
Prior art date
Application number
SG201006668-6A
Other languages
English (en)
Inventor
Ki Whan Hong
Tomohiro Yoshikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG165379A1 publication Critical patent/SG165379A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201006668-6A 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects SG165379A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71695405P 2005-09-15 2005-09-15
US76177506P 2006-01-25 2006-01-25

Publications (1)

Publication Number Publication Date
SG165379A1 true SG165379A1 (en) 2010-10-28

Family

ID=37420867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201006668-6A SG165379A1 (en) 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects

Country Status (21)

Country Link
US (2) US8580818B2 (fr)
EP (2) EP2275106A1 (fr)
JP (2) JP5179354B2 (fr)
KR (1) KR101299320B1 (fr)
AR (1) AR057520A1 (fr)
AU (1) AU2006289752B2 (fr)
BR (1) BRPI0616223A2 (fr)
CA (1) CA2620296C (fr)
CY (1) CY1112716T1 (fr)
DK (1) DK1942895T3 (fr)
ES (1) ES2378896T3 (fr)
HK (1) HK1122996A1 (fr)
IL (1) IL189751A0 (fr)
MY (1) MY145787A (fr)
NO (1) NO20081811L (fr)
PL (1) PL1942895T3 (fr)
PT (1) PT1942895E (fr)
RU (1) RU2411945C2 (fr)
SG (1) SG165379A1 (fr)
TW (1) TWI372053B (fr)
WO (1) WO2007032557A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065588A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad pulmonar obstructiva cronica
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH04193836A (ja) 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
JPH107590A (ja) 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
EP0946178A4 (fr) 1996-09-18 2003-05-07 Merck & Co Inc Traitement combine destine a reduire les risques de maladies cardio-vasculaires
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
WO1999024400A1 (fr) 1997-11-10 1999-05-20 Vyrex Corporation Esters de probucol et leurs utilisations
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
WO2000021507A2 (fr) 1998-10-12 2000-04-20 Andreas Bockelmann Composition pharmaceutiquement active
PT1272220E (pt) 2000-04-10 2006-10-31 Wald Nicholas John Formulacao para a prevencao de doencas cardiovasculares
US20020115728A1 (en) * 2000-09-05 2002-08-22 Roland Stocker Compositions and methods for treating cardiovascular disorders
EP1541175A3 (fr) * 2001-01-26 2006-04-12 Schering Corporation Combinaisons d'un inhibiteur de l'absorption de sterol avec un agent cardio-vasculaire pour le traitement des maladies cardio-vasculaires
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003192573A (ja) 2001-12-25 2003-07-09 Otsuka Pharmaceut Factory Inc 経口ゲル製剤
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
JP2005232059A (ja) 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
CN101193656B (zh) 2005-06-08 2011-03-02 兴和株式会社 甘油三酸酯降低剂
JP4193836B2 (ja) 2005-10-24 2008-12-10 ブラザー工業株式会社 インク噴射装置の製造方法

Also Published As

Publication number Publication date
JP5179354B2 (ja) 2013-04-10
PL1942895T3 (pl) 2012-07-31
TW200744597A (en) 2007-12-16
JP2013014605A (ja) 2013-01-24
EP1942895B1 (fr) 2012-02-01
EP2275106A1 (fr) 2011-01-19
NO20081811L (no) 2008-04-14
AU2006289752B2 (en) 2011-06-09
BRPI0616223A2 (pt) 2011-06-14
CA2620296A1 (fr) 2007-03-22
MY145787A (en) 2012-04-30
TWI372053B (en) 2012-09-11
RU2411945C2 (ru) 2011-02-20
US20140045889A1 (en) 2014-02-13
KR20080049822A (ko) 2008-06-04
PT1942895E (pt) 2012-03-29
HK1122996A1 (en) 2009-06-05
IL189751A0 (en) 2008-12-29
AU2006289752A1 (en) 2007-03-22
KR101299320B1 (ko) 2013-09-03
WO2007032557A1 (fr) 2007-03-22
US20090176826A1 (en) 2009-07-09
AR057520A1 (es) 2007-12-05
RU2008114512A (ru) 2009-10-20
JP5603393B2 (ja) 2014-10-08
DK1942895T3 (da) 2012-03-05
EP1942895A1 (fr) 2008-07-16
CY1112716T1 (el) 2016-02-10
CA2620296C (fr) 2013-10-22
US8580818B2 (en) 2013-11-12
ES2378896T3 (es) 2012-04-18
JP2009508804A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
MX353747B (es) Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
WO2009134973A8 (fr) Quinoléines et analogues apparentés en tant que modulateurs de sirtuine
EP1962601A4 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
EP2344475A4 (fr) Quinazolinone, quinolone et analogues apparentés en tant que modulateurs de sirtuine
WO2007136680A3 (fr) Éthers, amines secondaires et leurs dérivés utilisés en tant que modulateurs des récepteurs 5-ht2a de la sérotonine et utiles pour traiter les troubles liés à ces récepteurs
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2007120600A3 (fr) Dérivés de 3-pyridinylpyrazole comme modulateurs du récepteur 5-ht2a de la sérotonine utiles pour le traitement de troubles liés à ce dernier
WO2010123930A3 (fr) Thérapies à base de ligand de récepteur chimiosensible
NO20083026L (no) Terapeutisk middel for diabetes
WO2008127682A3 (fr) Combinaison d'une thérapie anticoagulante à un composé agissant en tant qu'inhibiteur de facteur xa
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
WO2007022947A3 (fr) Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
WO2006131322A3 (fr) Utilisation de derives de 2-oxo-1-pyrrolidone pour la preparation d'un medicament
WO2009121939A3 (fr) Composés c-aryl glycosides pour le traitement du diabète et de l'obésité
WO2009068659A3 (fr) Nouveau traitement de maladies par prédiction d'association médicamenteuse
WO2007142905A3 (fr) Dérivés de 1-sulfonylindazolylamine et de 1-sulfonylindazolylamide en tant que ligands de la 5-hydroxytryptamine-6
MY150474A (en) 6h-dibenzo [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antogonists
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
PL1951227T3 (pl) Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca
BR112012032813A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença ou condição.
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
SG165379A1 (en) Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects
DE602006018114D1 (de) Trifluornaphthalinderivat und flüssigkristallzusammensetzung, die die verbindung enthält